7292-74-2|2-Amino-2-(3-fluorophenyl)acetic acid| Ambeed

CAS No. :	7292-74-2
Formula :	C₈H₈FNO₂
M.W :	169.15
SMILES Code :	O=C(O)C(N)C1=CC=CC(F)=C1
MDL No. :	MFCD00049325
InChI Key :	LVYBCZIDQKJNFP-UHFFFAOYSA-N
Pubchem ID :	265434

Safety of [ 7292-74-2 ]

GHS Pictogram:
Signal Word:	Warning
Hazard Statements:	H302-H315-H319-H335
Precautionary Statements:	P261-P305+P351+P338

Application In Synthesis of [ 7292-74-2 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

Downstream synthetic route of [ 7292-74-2 ]

[ 7292-74-2 ] Synthesis Path-Downstream 1~49

1
[ 24424-99-5 ]
[ 7292-74-2 ]
[ 142121-94-6 ]

Yield	Reaction Conditions	Operation in experiment
69%		To a suspension of <strong>[7292-74-2]2-amino-2-(3-fluorophenyl)acetic acid</strong> (1.00 g, 5.91 mmol) in THF (30 ml) and water (30 ml), 2N sodium hydroxide (29.6 ml, 59.1 mmol) and di-tert-butyl dicarbonate (2.58 g, 1 1.8 mmol) were added and the reaction was stirred at RT for 15h. THF was evaporated, the aqueous phase was cooled and acidified with 37% HCl until pH 1. The desired compound was extracted with EtOAc and the organic phase was washed with brine, dried over Na2SO4 and evaporated to obtain 2-(tert-butoxycarbonylamino)-2-(3- fluorophenyl)acetic acid (1.10 g; 69% yield).
69%	With sodium hydroxide; In tetrahydrofuran; water; at 20℃; for 15h;	To a suspension of <strong>[7292-74-2]2-amino-2-(3-fluorophenyl)acetic acid</strong> (1.00 g, 5.91 mmol) in THF (30 ml) and water (30 ml), were added 2N sodium hydroxide (29.6 ml, 59.1 mmol) and di-tert-butyl dicarbonate (2.58 g, 11.8 mmol), and the reaction was stirred at RT for 15 hours. THF was evaporated, and the aqueous phase was cooled and acidified with 37% HCl until pH 1. The desired compound was extracted with EtOAc, and the organic phase was washed with brine, dried over Na2SO4 and evaporated to obtain 2-(tert-butoxycarbonylamino)-2-(3-fluorophenyl)acetic acid (1.10 g; 69% yield).

References: [1]Patent: WO2012/69275,2012,A1 .Location in patent: Page/Page column 64-65.
[2]Patent: US2012/134934,2012,A1 .Location in patent: Page/Page column 30.
[3]Journal of Medicinal Chemistry,1993,vol. 36,p. 314 - 319.

2
(3-Fluoro-phenyl)-[(E)-hydroxyimino]-acetic acid [ No CAS ]
[ 7292-74-2 ]

References: [1]Journal of Medicinal Chemistry,1993,vol. 36,p. 314 - 319.

3
[ 271583-22-3 ]
[ 7292-74-2 ]

References: [1]Synthetic Communications,2000,vol. 30,p. 1095 - 1102.

Yield	Reaction Conditions	Operation in experiment
		Substitution in the procedure of Example 3 for the N-tert.-butoxycarbonyl derivative of D-α-aminophenylacetic acid (also called D-α-tert.-butoxycarboxamidophenylacetic acid) of an equimolar weight of the N-tert.-butoxycarbonyl derivative of ... D-α-amino-m-methylphenylacetic acid, D-α-amino-p-chlorophenylacetic acid, D-α-amino-m-chlorophenylacetic acid, D-α-amino-p-fluorophenylacetic acid, D-α-amino-m-fluorophenylacetic acid, D-α-amino-p-aminophenylacetic acid, D-α-amino-p-dimethylaminophenylacetic acid, D-α-amino-m,p-dimethoxyphenylacetic acid, ...
		The hydantoin was hydrolyzed at reflux using 1 N NaOH giving 2-amino-2-(3-fluorophenyl)acetic acid which was esterified via Procedure H in methanol to give the title compound.

5
[ 271583-58-5 ]
[ 7292-74-2 ]

References: [1]Synthetic Communications,2000,vol. 30,p. 1095 - 1102.

6
[ 271583-37-0 ]
[ 7292-74-2 ]

References: [1]Synthetic Communications,2000,vol. 30,p. 1095 - 1102.

7
[ 456-48-4 ]
[ 7292-74-2 ]

References: [1]Synthetic Communications,2000,vol. 30,p. 1095 - 1102.

8
[ 501-00-8 ]
[ 7292-74-2 ]

References: [1]Journal of Medicinal Chemistry,1993,vol. 36,p. 314 - 319.

9
[ 7292-74-2 ]
(R)-1-[2-tert-Butoxycarbonylamino-2-(3-fluoro-phenyl)-acetyl]-pyrrolidine-2-carboxylic acid [ No CAS ]

References: [1]Journal of Medicinal Chemistry,1993,vol. 36,p. 314 - 319.

10
[ 7292-74-2 ]
C₂₀H₁₇Cl₃FNO₆ [ No CAS ]

References: [1]Journal of Medicinal Chemistry,1993,vol. 36,p. 314 - 319.

11
[ 7292-74-2 ]
C₃₂H₄₁FN₆O₇ [ No CAS ]

References: [1]Journal of Medicinal Chemistry,1993,vol. 36,p. 314 - 319.

12
[ 7292-74-2 ]
[2-{(S)-2-[(S)-1-(Benzyloxycarbonylamino-imino-methyl)-2-oxo-piperidin-3-ylcarbamoyl]-pyrrolidin-1-yl}-1-(3-fluoro-phenyl)-2-oxo-ethyl]-carbamic acid tert-butyl ester [ No CAS ]

References: [1]Journal of Medicinal Chemistry,1993,vol. 36,p. 314 - 319.

13
[ 7292-74-2 ]
Boc-D-Phg(F)-Pro-Arg-H*HOAc [ No CAS ]

References: [1]Journal of Medicinal Chemistry,1993,vol. 36,p. 314 - 319.

14
[ 7292-74-2 ]
rac-2-amino-2-(3-fluorophenyl)ethanol [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	With sodium tetrahydroborate; iodine; In tetrahydrofuran; at 0℃;Heating;	D,L-3-fluorophenylglycine (10 g, 59.2 mmol) was added to a suspension of NaBH4 (5.37 g, 142 mmol) in THF (200 mL). The suspension was cooled to 0 C., and an iodine solution (15 g, 59.2 mmol) in THF was added drop wise. The resulting solution was heated while stirring overnight. This solution was cooled to room temperature, quenched with a 20% KOH solution (150 mL) and extracted with DCM (3×). The organics were combined, dried over MgSO4 and the solvent was removed using a rotary evaporator. The product was purified by flash chromatography (0-10% MeOH/EtOAc) to yield 2-amino-2-(3-fluorophenyl)ethanol (I-8) as a white residue.
	With sodium tetrahydroborate; iodine; In tetrahydrofuran; at 0℃; for 20h;Reflux;	Step 1: Preparation of 2-amino- -(3-fluoro-phenyl)-ethanol Amino-(3-fluoro-phenyl)-acetic acid (1.8 g, 10 mmol), NaBH4 (0.95 g, 2.5 mmol) and THF (30 mL) were added dropwise to a solution of iodine (2.54 g, 10 mmol) in anhydrous THF (7 mL) through a pressure-equalizing addition funnel at 0 C. After the ceasing of the hydrogen gas, the reaction mixture was heated to reflux for 20 hours and then cooled to room temperature. The reaction was quenched with methanol, and then dissolved in 20% aqueous KOH. The reaction mixture was stirred overnight to give 1.4 g of crude 2-amino-2-(3-fluoro-phenyl)- ethanol which was directly used in the next step.
	With sodium tetrahydroborate; iodine; In tetrahydrofuran; at 0℃;Heating;	In step 2-1, D,L-3-fluorophenylglycine (10 g, 59.2 mmol) was added to a suspension Of NaBH4 (5.37 g, 142 mmol) in THF (200 mL). The suspension was cooled to 0 0C, and an iodine (15 g, 59.2 mmol) solution in THF was added drop- wise. The resulting solution was heated while stirring over-night. This solution was cooled to room temperature, quenched with a 20 % KOH solution (150 mL), and extracted with dichloro methane (3x). The organics were combined, dried over MgSO4 and the solvent removed using a rotary evaporator. The product was purified with flash chromatography (0 -10 % methanol/ethyl acetate) to yield 2-amino-2-(3-fluorophenyl)ethanol (2-1) as a white residue.

References: [1]ACS Medicinal Chemistry Letters,2015,vol. 6,p. 562 - 567.
[2]Patent: US2012/65184,2012,A1 .Location in patent: Page/Page column 37-38.
[3]Patent: WO2014/106606,2014,A1 .Location in patent: Page/Page column 64.
[4]Patent: WO2009/140128,2009,A2 .Location in patent: Page/Page column 102.

15
[ 7292-74-2 ]
[ 1196551-87-7 ]

References: [1]Patent: US2012/65184,2012,A1 .
[2]ACS Medicinal Chemistry Letters,2015,vol. 6,p. 562 - 567.
[3]Patent: WO2009/140128,2009,A2 .

16
[ 7292-74-2 ]
[ 1196551-88-8 ]

References: [1]Patent: US2012/65184,2012,A1 .
[2]ACS Medicinal Chemistry Letters,2015,vol. 6,p. 562 - 567.
[3]Patent: WO2009/140128,2009,A2 .

17
[ 7292-74-2 ]
[ 1196551-89-9 ]

References: [1]Patent: US2012/65184,2012,A1 .
[2]ACS Medicinal Chemistry Letters,2015,vol. 6,p. 562 - 567.
[3]Patent: WO2009/140128,2009,A2 .

18
[ 7292-74-2 ]
[ 1196551-90-2 ]

References: [1]Patent: US2012/65184,2012,A1 .
[2]ACS Medicinal Chemistry Letters,2015,vol. 6,p. 562 - 567.
[3]Patent: WO2009/140128,2009,A2 .

19
[ 7292-74-2 ]
[ 1365212-63-0 ]

References: [1]Patent: US2012/65184,2012,A1 .

20
[ 7292-74-2 ]
[ 1365212-76-5 ]

References: [1]Patent: US2012/65184,2012,A1 .

21
[ 7292-74-2 ]
[ 1365212-77-6 ]
(S)-6-(2-(3-fluorophenyl)-2,5-dihydro-1H-pyrrol-1-yl)imidazo[1,2-b]pyridazine-3-carboxamide [ No CAS ]

References: [1]Patent: US2012/65184,2012,A1 .

22
[ 7292-74-2 ]
[ 1379513-71-9 ]

References: [1]Patent: WO2012/69275,2012,A1 .
[2]Patent: US2012/134934,2012,A1 .

23
[ 7292-74-2 ]
[ 1379513-70-8 ]

References: [1]Patent: WO2012/69275,2012,A1 .
[2]Patent: US2012/134934,2012,A1 .

24
[ 7292-74-2 ]
[ 1617545-71-7 ]

References: [1]Patent: WO2014/106606,2014,A1 .

25
[ 7292-74-2 ]
[ 1196547-19-9 ]

References: [1]ACS Medicinal Chemistry Letters,2015,vol. 6,p. 562 - 567.

26
[ 91-02-1 ]
[ 7292-74-2 ]
3-(3-fluorophenyl)-1-phenylimidazo[1,5-a]pyridine [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
81%	With di-tert-butyl peroxide; iodine; In toluene; at 120℃; for 12h;Sealed tube;	General procedure: To a 10mL reaction tube were added L-Proline-MCM-41-Cu(OTf)2 (71mg, 0.045mmol), 2-benzoylpyridine 1 (0.3mmol), amino acid 2(0.9mmol), molecular iodine (0.045mmol), DTBP (0.75mmol), and toluene (2mL). The reaction tube was sealed and placed in an oil bath at room temperature. The reaction mixture was stirred at 120 C for 12 h. After being cooled to room temperature, the reaction mixture was diluted with 15 mL of EtOAc, and filtered. The L-Proline-MCM-41-Cu(OTf)2 complex was washed with EtOAc (25mL) and ethanol (2 5mL), and reused in the next run. The filtrate was concentrated in vacuo and the residue was purified by flash column chromatography on silica gel (petroleum ether: EtOAc 15:1-20:1) to provide the desired product 3.

References: [1]Journal of Organic Chemistry,2016,vol. 81,p. 3681 - 3687.
[2]Journal of Organometallic Chemistry,2019,vol. 881,p. 1 - 12.

27
[ 7292-74-2 ]
S-ethyl 3-(3-fluorophenyl)-3-((4-methoxyphenyl)amino)propanethioate [ No CAS ]

References: [1]Chemical Communications,2017,vol. 53,p. 3062 - 3065.

28
[ 7292-74-2 ]
methyl 3-(3-fluorophenyl)-3-((4-methoxyphenyl)amino)-2,2-dimethylpropanoate [ No CAS ]

References: [1]Chemical Communications,2017,vol. 53,p. 3062 - 3065.

29
[ 7292-74-2 ]
[ 104-94-9 ]
[ 64222-81-7 ]

References: [1]Chemical Communications,2017,vol. 53,p. 3062 - 3065.

30
[ 7292-74-2 ]
7-(3,5-dimethylisoxazol-4-yl)-2-(3-fluorophenyl)-2H-benzo[b][1,4]oxazin-3(4H)-one [ No CAS ]

References: [1]European Journal of Medicinal Chemistry,2018,vol. 152,p. 542 - 559.

31
[ 7292-74-2 ]
C₁₄H₉BrFNO₂ [ No CAS ]

References: [1]European Journal of Medicinal Chemistry,2018,vol. 152,p. 542 - 559.

32
[ 7292-74-2 ]
C₁₄H₁₀Br₂FNO₂ [ No CAS ]

References: [1]European Journal of Medicinal Chemistry,2018,vol. 152,p. 542 - 559.

33
[ 7292-74-2 ]
C₈H₅BrClFO [ No CAS ]

References: [1]European Journal of Medicinal Chemistry,2018,vol. 152,p. 542 - 559.

34
[ 7292-74-2 ]
[ 24805-50-3 ]

Yield	Reaction Conditions	Operation in experiment
		General procedure: To a solution ofDL-methionine (3.0 g, 20.1 mmol) in H2O (50 mL) was added 30% HBr (20 mL). The reaction mixture was stirred at 0 C for 10 min. A solution of sodium nitrite (1.7 g, 24 mmol) in H2O (50 mL) was added. The reaction mixture was stirred at 0 C for 30 min and thenwarmed to rt for 3 h. The reaction mixture was extracted withEtOAc (100 mL 3). The organic layer was washed with brine and dried over Na2SO4. The solid was filtered off, and the filtrate was concentrated under reduced pressure to give 3.6 g of intermediate 35c (83% yield).

References: [1]European Journal of Medicinal Chemistry,2018,vol. 152,p. 542 - 559.

35
[ 7292-74-2 ]
[ 1196546-34-5 ]

References: [1]Patent: WO2009/140128,2009,A2 .

36
[ 7292-74-2 ]
[ 643-79-8 ]
C₁₆H₁₂FNO₃ [ No CAS ]

References: [1]ACS Medicinal Chemistry Letters,2019,vol. 10,p. 869 - 873.

37
[ 7292-74-2 ]
C₂₂H₁₅F₂N₃O₄ [ No CAS ]

References: [1]ACS Medicinal Chemistry Letters,2019,vol. 10,p. 869 - 873.

38
[ 7292-74-2 ]
C₂₂H₁₇F₂N₃O₂ [ No CAS ]

References: [1]ACS Medicinal Chemistry Letters,2019,vol. 10,p. 869 - 873.

39
[ 7292-74-2 ]
N-(3-fluoro-4-((6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)quinazolin-4-yl)amino)phenyl)-2-(3-fluorophenyl)-2-(1-oxoisoindolin-2-yl)acetamide [ No CAS ]

References: [1]ACS Medicinal Chemistry Letters,2019,vol. 10,p. 869 - 873.

40
[ 7292-74-2 ]
C₁₆H₁₁ClFNO₂ [ No CAS ]

References: [1]ACS Medicinal Chemistry Letters,2019,vol. 10,p. 869 - 873.

41
[ 550313-06-9 ]
[ 7292-74-2 ]

References: [1]Patent: CN109824531,2019,A .

42
5-(m-fluorophenyl)hydantoin [ No CAS ]
[ 7292-74-2 ]

Yield	Reaction Conditions	Operation in experiment
	With potassium carbonate; In water; at 178℃; under 18751.9 Torr; for 0.0666667h;	The aqueous solution of 5-(m-fluorophenyl)-hydantoin (Hayin) obtained above and 276 g of an aqueous solution of potassium carbonate having a mass percentage of 50% by weight (hyperin: potassium ion = 1.0: 2.0)At the same time, the metering pump is pumped into the microchannel reactor, and the flow rate in the hyane microchannel is 58.9g/min.The flow rate of the aqueous solution of potassium carbonate in the microchannel is 25.79 g/min.The temperature of the control reaction is 168 C, the pressure is 2.0 MPa, and the residence time is 4 min (ie, the time during which the reaction liquid flows through the microchannel).The liquid flowing out is a clear yellowish transparent liquid, and the liquid is subjected to deamination and carbon dioxide to obtain 845.2447 g of an aqueous solution of potassium p-fluorophenylglycine.The mass percentage of fluorophenylglycine in the middle is 20.01% by weight, the mass percentage of potassium ion is 9.23% by weight, and the yield of m-fluorophenylglycine is 99.9% or more. The hydrolyzate obtained above is introduced into carbon dioxide gas, the pressure of the carbon dioxide gas is 0.3 MPa, the neutralization temperature is 20 C, and the stirring speed is 120 r/min.The carbon dioxide neutralization end point was pH 7.8, the solid was filtered off, washed with water, and dried to obtain 138.0841 g of m-fluorophenylglycine product, the main content was 98 wt%.The product is in the form of powder and undergoes recrystallization operation to obtain a crystalline DL-o-fluorophenylglycine product having a purity of 99.5 wt% or more, and the recrystallization mother liquor is recycled.The filtrate is an aqueous solution of potassium hydrogencarbonate containing o-fluorophenylglycine, and the mass of the filtrate is 760.5740 g, wherein the mass percentage of potassium ions is 10.26 wt%.The mass percentage of m-fluorophenylglycine is 4.45 wt%, and the filtrate is decarburized by heating, concentrated to a potassium ion mass percentage of 30 wt%, and recycled to the next batch of hydantoin hydrolysis.The mass of the mother liquid obtained after decarburization and concentration was 260.1142 g, and the mass percentage of the intermediate fluorophenylglycine was 13.0% by weight.

References: [1]Patent: CN109824531,2019,A .Location in patent: Paragraph 0046-0048.

43
[ 108-30-5 ]
[ 7292-74-2 ]
C₁₂H₁₂FNO₅ [ No CAS ]

References: [1]ACS Chemical Neuroscience,2020,vol. 11,p. 1996 - 2008.

44
[ 7292-74-2 ]
C₁₂H₁₀FNO₄ [ No CAS ]

References: [1]ACS Chemical Neuroscience,2020,vol. 11,p. 1996 - 2008.

45
[ 7292-74-2 ]
C₂₃H₂₁F₄N₃O₃ [ No CAS ]

References: [1]ACS Chemical Neuroscience,2020,vol. 11,p. 1996 - 2008.

46
[ 7292-74-2 ]
methyl 2-(7-bromo-1-oxoisoquinolin-2(1H)-yl)-2-(3-fluorophenyl)acetate [ No CAS ]

References: [1]Patent: WO2020/257632,2020,A1 .

47
[ 7292-74-2 ]
methyl 2-(7-bromo-4-oxoquinazolin-3(4H)-yl)-2-(3-fluorophenyl)acetate [ No CAS ]

References: [1]Patent: WO2020/257632,2020,A1 .

48
[ 67-56-1 ]
[ 7292-74-2 ]
methyl 2-amino-2-(3-fluorophenyl)acetate [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
6.49 g	With thionyl chloride; at 0 - 60℃; for 16.5h;	Thionyl chloride (7. /2 ml, 0.106 moi) was added dropwise to a mixture of 2-amino-2- (3-fiuoropheny)acetic acid (6.0 g, 0.035 mol) in methanol (100 L) at 0C. The reaction was stirred at room temperature for 30 minutes, then at 6QC for 16 hours. The solvents were removed under reduced pressure, and the residue was dissolved in EtOAc (150 mL). The organic layer was washed with saturated brine and saturated NaHC03, dried (Na2S04) and concentrated to give the title compound, used without further purification (6.49 g).1H NM (500 MHz, de-DMSO) d 7.35 (m, 1 H) 7.20 (d, 1 H) 7.15 (d, 1 H) 7.03 (m, 1 H) 3.74 (s, 3H).

References: [1]Patent: WO2020/257632,2020,A1 .Location in patent: Page/Page column 62; 72-73.

49
[ 7292-74-2 ]
[ 106-49-0 ]
[ 67-68-5 ]
2-(3-fluorophenyl)-6-methylquinazoline [ No CAS ]

References: [1]Chemical Communications,2021,vol. 57,p. 5414 - 5417.

Historical Records

Technical Information

• Alkyl Halide Occurrence • Arndt-Eistert Homologation • Hunsdiecker-Borodin Reaction • Passerini Reaction • Preparation of Amines • Preparation of Carboxylic Acids • Reactions of Amines • Reactions of Carboxylic Acids • Schmidt Reaction • Specialized Acylation Reagents-Ketenes • Ugi Reaction

Precautionary Statements-General
Code	Phrase
P101	If medical advice is needed,have product container or label at hand.
P102	Keep out of reach of children.
P103	Read label before use
Prevention
Code	Phrase
P201	Obtain special instructions before use.
P202	Do not handle until all safety precautions have been read and understood.
P210	Keep away from heat/sparks/open flames/hot surfaces. - No smoking.
P211	Do not spray on an open flame or other ignition source.
P220	Keep/Store away from clothing/combustible materials.
P221	Take any precaution to avoid mixing with combustibles
P222	Do not allow contact with air.
P223	Keep away from any possible contact with water, because of violent reaction and possible flash fire.
P230	Keep wetted
P231	Handle under inert gas.
P232	Protect from moisture.
P233	Keep container tightly closed.
P234	Keep only in original container.
P235	Keep cool
P240	Ground/bond container and receiving equipment.
P241	Use explosion-proof electrical/ventilating/lighting/equipment.
P242	Use only non-sparking tools.
P243	Take precautionary measures against static discharge.
P244	Keep reduction valves free from grease and oil.
P250	Do not subject to grinding/shock/friction.
P251	Pressurized container: Do not pierce or burn, even after use.
P260	Do not breathe dust/fume/gas/mist/vapours/spray.
P261	Avoid breathing dust/fume/gas/mist/vapours/spray.
P262	Do not get in eyes, on skin, or on clothing.
P263	Avoid contact during pregnancy/while nursing.
P264	Wash hands thoroughly after handling.
P265	Wash skin thouroughly after handling.
P270	Do not eat, drink or smoke when using this product.
P271	Use only outdoors or in a well-ventilated area.
P272	Contaminated work clothing should not be allowed out of the workplace.
P273	Avoid release to the environment.
P280	Wear protective gloves/protective clothing/eye protection/face protection.
P281	Use personal protective equipment as required.
P282	Wear cold insulating gloves/face shield/eye protection.
P283	Wear fire/flame resistant/retardant clothing.
P284	Wear respiratory protection.
P285	In case of inadequate ventilation wear respiratory protection.
P231 + P232	Handle under inert gas. Protect from moisture.
P235 + P410	Keep cool. Protect from sunlight.
Response
Code	Phrase
P301	IF SWALLOWED:
P304	IF INHALED:
P305	IF IN EYES:
P306	IF ON CLOTHING:
P307	IF exposed:
P308	IF exposed or concerned:
P309	IF exposed or if you feel unwell:
P310	Immediately call a POISON CENTER or doctor/physician.
P311	Call a POISON CENTER or doctor/physician.
P312	Call a POISON CENTER or doctor/physician if you feel unwell.
P313	Get medical advice/attention.
P314	Get medical advice/attention if you feel unwell.
P315	Get immediate medical advice/attention.
P320
P302 + P352	IF ON SKIN: wash with plenty of soap and water.
P321
P322
P330	Rinse mouth.
P331	Do NOT induce vomiting.
P332	IF SKIN irritation occurs:
P333	If skin irritation or rash occurs:
P334	Immerse in cool water/wrap n wet bandages.
P335	Brush off loose particles from skin.
P336	Thaw frosted parts with lukewarm water. Do not rub affected area.
P337	If eye irritation persists:
P338	Remove contact lenses, if present and easy to do. Continue rinsing.
P340	Remove victim to fresh air and keep at rest in a position comfortable for breathing.
P341	If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P342	If experiencing respiratory symptoms:
P350	Gently wash with plenty of soap and water.
P351	Rinse cautiously with water for several minutes.
P352	Wash with plenty of soap and water.
P353	Rinse skin with water/shower.
P360	Rinse immediately contaminated clothing and skin with plenty of water before removing clothes.
P361	Remove/Take off immediately all contaminated clothing.
P362	Take off contaminated clothing and wash before reuse.
P363	Wash contaminated clothing before reuse.
P370	In case of fire:
P371	In case of major fire and large quantities:
P372	Explosion risk in case of fire.
P373	DO NOT fight fire when fire reaches explosives.
P374	Fight fire with normal precautions from a reasonable distance.
P376	Stop leak if safe to do so. Oxidising gases (section 2.4) 1
P377	Leaking gas fire: Do not extinguish, unless leak can be stopped safely.
P378
P380	Evacuate area.
P381	Eliminate all ignition sources if safe to do so.
P390	Absorb spillage to prevent material damage.
P391	Collect spillage. Hazardous to the aquatic environment
P301 + P310	IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician.
P301 + P312	IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell.
P301 + P330 + P331	IF SWALLOWED: Rinse mouth. Do NOT induce vomiting.
P302 + P334	IF ON SKIN: Immerse in cool water/wrap in wet bandages.
P302 + P350	IF ON SKIN: Gently wash with plenty of soap and water.
P303 + P361 + P353	IF ON SKIN (or hair): Remove/Take off Immediately all contaminated clothing. Rinse SKIN with water/shower.
P304 + P312	IF INHALED: Call a POISON CENTER or doctor/physician if you feel unwell.
P304 + P340	IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing.
P304 + P341	IF INHALED: If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P305 + P351 + P338	IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
P306 + P360	IF ON CLOTHING: Rinse Immediately contaminated CLOTHING and SKIN with plenty of water before removing clothes.
P307 + P311	IF exposed: call a POISON CENTER or doctor/physician.
P308 + P313	IF exposed or concerned: Get medical advice/attention.
P309 + P311	IF exposed or if you feel unwell: call a POISON CENTER or doctor/physician.
P332 + P313	IF SKIN irritation occurs: Get medical advice/attention.
P333 + P313	IF SKIN irritation or rash occurs: Get medical advice/attention.
P335 + P334	Brush off loose particles from skin. Immerse in cool water/wrap in wet bandages.
P337 + P313	IF eye irritation persists: Get medical advice/attention.
P342 + P311	IF experiencing respiratory symptoms: call a POISON CENTER or doctor/physician.
P370 + P376	In case of fire: Stop leak if safe to Do so.
P370 + P378	In case of fire:
P370 + P380	In case of fire: Evacuate area.
P370 + P380 + P375	In case of fire: Evacuate area. Fight fire remotely due to the risk of explosion.
P371 + P380 + P375	In case of major fire and large quantities: Evacuate area. Fight fire remotely due to the risk of explosion.
Storage
Code	Phrase
P401
P402	Store in a dry place.
P403	Store in a well-ventilated place.
P404	Store in a closed container.
P405	Store locked up.
P406	Store in corrosive resistant/ container with a resistant inner liner.
P407	Maintain air gap between stacks/pallets.
P410	Protect from sunlight.
P411
P412	Do not expose to temperatures exceeding 50 oC/ 122 oF.
P413
P420	Store away from other materials.
P422
P402 + P404	Store in a dry place. Store in a closed container.
P403 + P233	Store in a well-ventilated place. Keep container tightly closed.
P403 + P235	Store in a well-ventilated place. Keep cool.
P410 + P403	Protect from sunlight. Store in a well-ventilated place.
P410 + P412	Protect from sunlight. Do not expose to temperatures exceeding 50 oC/122oF.
P411 + P235	Keep cool.
Disposal
Code	Phrase
P501	Dispose of contents/container to ...
P502	Refer to manufacturer/supplier for information on recovery/recycling

Physical hazards
Code	Phrase
H200	Unstable explosive
H201	Explosive; mass explosion hazard
H202	Explosive; severe projection hazard
H203	Explosive; fire, blast or projection hazard
H204	Fire or projection hazard
H205	May mass explode in fire
H220	Extremely flammable gas
H221	Flammable gas
H222	Extremely flammable aerosol
H223	Flammable aerosol
H224	Extremely flammable liquid and vapour
H225	Highly flammable liquid and vapour
H226	Flammable liquid and vapour
H227	Combustible liquid
H228	Flammable solid
H229	Pressurized container: may burst if heated
H230	May react explosively even in the absence of air
H231	May react explosively even in the absence of air at elevated pressure and/or temperature
H240	Heating may cause an explosion
H241	Heating may cause a fire or explosion
H242	Heating may cause a fire
H250	Catches fire spontaneously if exposed to air
H251	Self-heating; may catch fire
H252	Self-heating in large quantities; may catch fire
H260	In contact with water releases flammable gases which may ignite spontaneously
H261	In contact with water releases flammable gas
H270	May cause or intensify fire; oxidizer
H271	May cause fire or explosion; strong oxidizer
H272	May intensify fire; oxidizer
H280	Contains gas under pressure; may explode if heated
H281	Contains refrigerated gas; may cause cryogenic burns or injury
H290	May be corrosive to metals
Health hazards
Code	Phrase
H300	Fatal if swallowed
H301	Toxic if swallowed
H302	Harmful if swallowed
H303	May be harmful if swallowed
H304	May be fatal if swallowed and enters airways
H305	May be harmful if swallowed and enters airways
H310	Fatal in contact with skin
H311	Toxic in contact with skin
H312	Harmful in contact with skin
H313	May be harmful in contact with skin
H314	Causes severe skin burns and eye damage
H315	Causes skin irritation
H316	Causes mild skin irritation
H317	May cause an allergic skin reaction
H318	Causes serious eye damage
H319	Causes serious eye irritation
H320	Causes eye irritation
H330	Fatal if inhaled
H331	Toxic if inhaled
H332	Harmful if inhaled
H333	May be harmful if inhaled
H334	May cause allergy or asthma symptoms or breathing difficulties if inhaled
H335	May cause respiratory irritation
H336	May cause drowsiness or dizziness
H340	May cause genetic defects
H341	Suspected of causing genetic defects
H350	May cause cancer
H351	Suspected of causing cancer
H360	May damage fertility or the unborn child
H361	Suspected of damaging fertility or the unborn child
H361d	Suspected of damaging the unborn child
H362	May cause harm to breast-fed children
H370	Causes damage to organs
H371	May cause damage to organs
H372	Causes damage to organs through prolonged or repeated exposure
H373	May cause damage to organs through prolonged or repeated exposure
Environmental hazards
Code	Phrase
H400	Very toxic to aquatic life
H401	Toxic to aquatic life
H402	Harmful to aquatic life
H410	Very toxic to aquatic life with long-lasting effects
H411	Toxic to aquatic life with long-lasting effects
H412	Harmful to aquatic life with long-lasting effects
H413	May cause long-lasting harmful effects to aquatic life
H420	Harms public health and the environment by destroying ozone in the upper atmosphere

{[proInfo.proName]}

CAS No.: 7292-74-2

{[proInfo.proName]}

CAS No.: 7292-74-2

Alternative Products

Product Details of [ 7292-74-2 ]

Safety of [ 7292-74-2 ]

Application In Synthesis of [ 7292-74-2 ]

[ 7292-74-2 ] Synthesis Path-Downstream 1~49

Related Products

Historical Records

Technical Information

Categories

Precautionary Statements-General

Prevention

Response

Storage

Disposal

Physical hazards

Health hazards

Environmental hazards

Inquiry

Molarity Calculator

Total Compounds Calculator

Dissolution Calculator